Meet Metsera – we are on a mission to reduce the physical, emotional and economic burdens of #obesity as a driver of diseases. We believe that healthy, sustainable weight loss can be empowering, but there is still a significant unmet need for effective therapies. With our fully integrated approach, we plan to establish a cycle of continuous and responsive innovation for a fast-evolving market. Learn more in our release here: https://metsera.com/news
About us
Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Founded in 2022 by Population Health Partners and ARCH Venture Partners, Metsera has raised $290 million in financing from leading healthcare investors and is based in New York City.
- Website
-
https://metsera.com/
External link for Metsera
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Type
- Privately Held